Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions

MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.

Subsidie
€ 2.100.238
2022

Projectdetails

Introduction

MITI will develop and mature a novel, ground-breaking technology for high precision non-ionizing metabolic imaging, enabling fast and non-invasive detection of the markers of metabolic processes e.g., cell proliferation and energy metabolism.

Benefits of the Technology

Using the results of metabolic imaging, medical specialists will be able to establish the effectiveness of therapies and determine the specific disease months sooner than is possible with currently available technologies. This will increase patient well-being and reduce the costs of healthcare as unsuccessful therapies can be stopped and replaced earlier by more effective (personalized) therapies.

Market Potential

This solution addresses an enormous market with millions of patients worldwide. MITI builds on the results of NICI in which the basic key marker molecules for metabolic imaging on MRI platforms were successfully discovered (1H, 2H, 31P, and 23Na), including the capability to detect these by inserts on 7T MRI platforms.

Project Components

MITI comprises:

  1. The further development and testing of a basic double tuned metabolic imaging set (detecting 1H and one of the following molecules: 2H, 31P, or 23Na).
  2. Validation of the basic technology to detect metabolic markers in specific use cases:
    • Cell proliferation metabolism after treatment of lung tumors and pancreatic cancer with liver metastases.
    • Cardiac drug mechanisms.
    • Energy metabolism of muscle dystrophy.
  3. Development of an advanced quadruple tuned metabolic imaging set that will broaden the spectrum of metabolic processes that can be successfully viewed in parallel.

Future Plans

The results of the use cases will be used for power calculations for clinical trials to be conducted after MITI. The MITI partners aim to commercialize the technology, directly after MITI by providing it to clinicians in research centers and within 3 years after MITI to general medical centers.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.100.238
Totale projectbegroting€ 2.100.238

Tijdlijn

Startdatum1-4-2022
Einddatum30-9-2025
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • UNIVERSITAIR MEDISCH CENTRUM UTRECHTpenvoerder
  • TESLA DYNAMIC COILS BV
  • Fondazione Stella Maris
  • UNIVERSITAETSKLINIKUM ESSEN
  • THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Land(en)

NetherlandsItalyGermanyUnited Kingdom

Vergelijkbare projecten binnen EIC Transition

EIC Transition

MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care

MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.

€ 2.495.127
EIC Transition

Early detection of treatment response in breast cancer

The project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects.

€ 2.499.229
EIC Transition

Truly portable MRI for extremity and brain imaging anywhere & everywhere

The NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally.

€ 2.494.415
EIC Transition

Magnetic Resonance at the Scale of a Cell

The HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses.

€ 1.998.750

Vergelijkbare projecten uit andere regelingen

ERC Starting...

Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment

This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.

€ 1.497.756
ERC Starting...

Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI

Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.

€ 1.497.669
ERC Starting...

Hyperpolarized Magnetic Resonance at the point-of-care

HYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods.

€ 1.499.968
EIC Pathfinder

REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTION

RETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine.

€ 3.126.347
ERC Starting...

Revealing liver micrometastases in vivo using ultra-high definition MRI

MicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights.

€ 1.998.456